Migraine in the era of precision medicine
- 1 March 2016
- journal article
- research article
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 4 (6) , 105
Abstract
Migraine is a common neurovascular disorder in the neurologic clinics whose mechanisms have been explored for several years. The aura has been considered to be attributed to cortical spreading depression (CSD) and dysfunction of the trigeminovascular system is the key factor that has been considered in the pathogenesis of migraine pain. Moreover, three genes (CACNA1A, ATP1A2, and SCN1A) have come from studies performed in individuals with familial hemiplegic migraine (FHM), a monogenic form of migraine with aura. Therapies targeting on the neuropeptids and genes may be helpful in the precision medicine of migraineurs. 5-hydroxytryptamine (5-HT) receptor agonists and calcitonin gene-related peptide (CGRP) receptor antagonists have demonstrated efficacy in the acute specific treatment of migraine attacks. Therefore, ongoing and future efforts to find new vulnerabilities of migraine, unravel the complexity of drug therapy, and perform biomarker-driven clinical trials are necessary to improve outcomes for patients with migraine.Keywords
This publication has 99 references indexed in Scilit:
- Effect of NOS3 gene polymorphism on response to Tricyclic antidepressants in migraine attacks2014
- Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patientsCephalalgia, 2013
- RAMPs and CGRP Receptors2012
- Increased Susceptibility to Cortical Spreading Depression in the Mouse Model of Familial Hemiplegic Migraine Type 2PLOS Genetics, 2011
- EFNS guideline on the drug treatment of migraine – revised report of an EFNS task forceEuropean Journal of Neurology, 2009
- Structures of CaV2 Ca2+/CaM-IQ Domain Complexes Reveal Binding Modes that Underlie Calcium-Dependent Inactivation and FacilitationStructure, 2008
- Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraineNeurology, 2008
- Migraine: a complex genetic disorderThe Lancet Neurology, 2007
- Calcitonin Gene–Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of MigraineNew England Journal of Medicine, 2004
- Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5‐hydroxy‐tryptamine (5‐HT1B/1D) receptorsBritish Journal of Pharmacology, 1997